Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

NCT07281833 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HR-positive Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Capivasertib

Sponsor

West German Study Group

Collaborators

[object Object]